Systemic Anti-Cancer Therapy Regimen Library
LYM Relapsed/Refractory - pembrolizumab Q3W [flat dosing]
Treatment Overview
Maximum of 24 months of treatment is recommended.
Cycle 1 (and all further cycles) - 21 days
Cycle details
Cycle 1 (and all further cycles) - 21 days
| Medication | Dose | Route | Days | Max Duration |
|---|---|---|---|---|
| pembrolizumab | 200 mg flat dosing | intravenous | 1 | 30 minutes |
Full details
Cycle 1 (and all further cycles) - 21 days
Day: 1
| Medication | Dose | Route | Max duration | Details |
|---|---|---|---|---|
| pembrolizumab | 200 mg flat dosing | intravenous | 30 minutes |
Instructions:
Administer via a sterile, non-pyrogenic, low protein binding 0.2 to 5 micron in-line or add-on filter. |
Supportive Care Factors
| Factor | Value |
|---|---|
| Emetogenicity: | Minimal |
| Irradiated blood components: | Variable |
Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.
Irradiated blood components: Required for Hodgkin lymphoma patients at all stages of disease and therapy. Continue indefinitely.
References
Zinzani, P.L., R. Chen, H. Lee. 2018. " Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma". Blood 132 (Suppl 1), 2900. Accessed September 08, 2019. https://doi.org/10.1182/blood-2018-99-117045.
Zinzani, P.L., C.Thieblemont, V. Melnichenko, et al. 2017. "Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): updated analysis of the keynote-170 phase 2 trial". Blood. 2017; 130(Suppl): 2833.
Merck Sharp & Dohme (New Zealand) Limited. Keytruda New Zealand Data Sheet 16 September 2021 https://www.medsafe.govt.nz/profs/Datasheet/k/Keytruda.pdf (Accessed 16 February 2022).
New Zealand Blood Service Transfusion Medicine Handbook Third Edition, 2016 https://www.nzblood.co.nz/assets/Transfusion-Medicine/PDFs/111G122.pdf (accessed 16 June 2022).
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.